• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

    22.29 +0.09 (+0.41%)
    Streaming Delayed Price Updated: 12:13 PM EDT, Apr 30, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 242,122
    Open 22.20
    Bid (Size) 22.29 (100)
    Ask (Size) 22.30 (200)
    Prev. Close 22.20
    Today's Range 22.19 - 22.52
    52wk Range 14.18 - 28.35
    Shares Outstanding 162,625,379
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting
    From Acadia Pharmaceuticals Inc.
    Via Business Wire

    Performance

    YTD
    -15.2%
    -15.2%
    1 Month
    +5.8%
    +5.8%
    3 Month
    -13.0%
    -13.0%
    6 Month
    -1.1%
    -1.1%
    1 Year
    +54.5%
    +54.5%

    More News

    Read More
    News headline image
    Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal
    Via MarketMinute
    News headline image
    Soleno Therapeutics: A Masterclass in Rare Disease Redemption and the $2.9B Exit
    Via Finterra
    Topics Economy Intellectual Property
    ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Surpasses $1 Billion Revenue Milestone in 2025, Beats Q4 EPS Estimates ↗
    Via Chartmill
    ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) Emerges as a Value Stock with Strong Fundamentals ↗
    Via Chartmill
    News headline image
    Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal as VYKAT™ XR Sales Soar
    Via MarketMinute
    Topics Intellectual Property
    News headline image
    Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth Momentum and Technical Setup ↗
    Via Chartmill
    News headline image
    Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts ↗
    Via Stocktwits
    News headline image
    ACADIA (ACAD) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50% ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    ACAD Stock Slumps 8% After Hours On Hurdle To EU Approval For Genetic Disorder Drug ↗
    Via Stocktwits
    News headline image
    Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
    From Acadia Pharmaceuticals Inc.
    Via Business Wire

    Frequently Asked Questions

    Is ACADIA Pharmaceuticals Inc. - Common Stock publicly traded?
    Yes, ACADIA Pharmaceuticals Inc. - Common Stock is publicly traded.
    What exchange does ACADIA Pharmaceuticals Inc. - Common Stock trade on?
    ACADIA Pharmaceuticals Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for ACADIA Pharmaceuticals Inc. - Common Stock?
    The ticker symbol for ACADIA Pharmaceuticals Inc. - Common Stock is ACAD on the Nasdaq Stock Market
    What is the current price of ACADIA Pharmaceuticals Inc. - Common Stock?
    The current price of ACADIA Pharmaceuticals Inc. - Common Stock is 22.29
    When was ACADIA Pharmaceuticals Inc. - Common Stock last traded?
    The last trade of ACADIA Pharmaceuticals Inc. - Common Stock was at 04/30/26 12:13 PM ET
    What is the market capitalization of ACADIA Pharmaceuticals Inc. - Common Stock?
    The market capitalization of ACADIA Pharmaceuticals Inc. - Common Stock is 3.62B
    How many shares of ACADIA Pharmaceuticals Inc. - Common Stock are outstanding?
    ACADIA Pharmaceuticals Inc. - Common Stock has 4B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.